Global biopharma leader drives digital innovation, data sciences, and next-generation automation approaches with Genedata’s cloud-based Biopharma Platform
BASEL, Switzerland, July 31, 2024 /PRNewswire-PRWeb/ — Genedata, a leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that GSK, a leading biopharma company, has extended the use of Genedata Biologics® to new application areas in data sciences, analytics, and R&D automation.
Access to structured and organized data from Genedata Biologics enables our data science, predictive modelling, and AI/ML projects as we continue our work to optimize the clinical effectiveness of our medicines. Steve Martin, Ph.D., VP and Head of Large Molecule Discovery at GSK
“We’ve migrated our on-premise hosted version of Biologics to Genedata’s SaaS platform to leverage the various benefits that cloud-hosting offers. We continue to integrate data workflows for design, production, screening, characterization and engineering of novel biotherapeutics whilst developing features to handle bi- and multi-specific modalities,” said Steve Martin, Ph.D., VP and Head of Large Molecule Discovery. “At GSK we use leading edge data and platform technologies to discover and develop new medicines and vaccines better and faster to positively impact the health of people at scale. Access to structured and organized data from Genedata Biologics enables our data science, predictive modelling, and AI/ML projects as we continue our work to optimize the clinical effectiveness of our medicines.”
Since its initial deployment in 2013, Genedata Biologics has become a core part of GSK’s Large Molecule Discovery team’s antibody discovery data platform, automating lab operations and data streams from diverse discovery projects. Genedata Biologics directly integrates with GSK’s automation systems to generate, express, and purify large numbers of candidates, followed by high-throughput characterization and lead evaluation. Automated cloning and expression runs generate a substantial number of data and metadata points that Genedata Biologics can store and help cascade to downstream consumers across the organization.
The system offers real-time access to all critical data to GSK’s scientists, managers, and executives, which promotes synergies within and across projects. The Genedata platform also enables users across R&D to monitor program performance, resource and project planning, and task prioritization.
“We are pleased that GSK, one of the leading innovators in the development of novel biopharmaceuticals, has decided to expand the use of Genedata Biologics as their foundation platform for guided biotherapeutics discovery,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Digital transformation is opening new horizons in biopharmaceutical R&D, and we are excited that our platform is helping GSK to develop innovative biotherapies faster.”
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn | X | YouTube
Contact
Allison Kurz
Genedata
Public Relations
pr@genedata.com
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Media Contact
Allison Kurz, Genedata, +41 61 511 84 00, pr@genedata.com, www.genedata.com
View original content to download multimedia:https://www.prweb.com/releases/gsk-leverages-genedata-biologics-as-end-to-end-automation-and-data-science-platform-302207516.html
SOURCE Genedata
